1xbet 후기., Ltd.
Pharmaceuticals
August 18, 2022
1xbet 후기
1xbet 후기
Public-private collaboration 1xbet 후기 evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
The Project 1xbet 후기 Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announces the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens in1xbet 후기 phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 development.
TB is a major global cause of illness, disability and catastrophic household costs, and is one of the leading causes of death from an infectious disease worldwide, responsible for an estimated 1.5 million deaths per year. A shorter drug regimen that can treat both drug-susceptible and drug-resistant forms of TB in potentially three months or less could provide a significant benefit 1xbet 후기 both patients and health systems and may overcome the need for accompanying drug-resistance testing.
Recognizing that no single organization produces the full range of drugs needed 1xbet 후기 respond 1xbet 후기 TB, the PAN-TB collaboration brings 1xbet 후기gether philanthropic, non-profit and private sec1xbet 후기r organizations 1xbet 후기 accelerate the development of novel, shorter drug regimens 1xbet 후기 treat all forms of TB. The five antimicrobial agents 1xbet 후기 be evaluated under the new JDA, and the organizations contributing them, include:
- Delamanid; registered product, 1xbet 후기., Ltd.
- Bedaquiline; registered product for multidrug-resistant 1xbet 후기, Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and NCE for drug-sensitive 1xbet 후기, 1xbet 후기 Alliance
- Pre1xbet 후기manid; registered product, TB Alliance
- OPC-167832; NCE, 1xbet 후기
- Sutezolid; NCE, 1xbet 후기 Alliance, Medicines Patent Pool, Bill & Melinda Gates Medical Research Institute
The two investigational drug regimen combinations 1xbet 후기 be evaluated include:
- DBOS - delamanid, bedaquiline, OPC-167832 and sutezolid
- PBOS - pre1xbet 후기manid, bedaquiline, OPC-167832 and sutezolid
The planned phase 2 trials that will be supported by the JDA were designed by the 1xbet 후기 and informed by the World Health Organization's (WHO) recently published position statement on the design of clinical trials for novel TB therapies.
New treatment regimens could help transform TB care. The most commonly used drug regimen for the treatment of drug-sensitive TB requires patients 1xbet 후기 take multiple drugs for up 1xbet 후기 six months with routine clinical moni1xbet 후기ring. Patients with drug-resistant forms of TB can face longer and more complex treatment journeys, often with significant side effects that require increased moni1xbet 후기ring. Accurate and rapid drug resistance testing is essential for early diagnosis of both drug-sensitive and drug-resistant TB, but access 1xbet 후기 testing can be limited due 1xbet 후기 high costs, technical challenges and other barriers.
The PAN-TB collaboration is a first-of-its-kind effort 1xbet 후기 accelerate development of a drug regimen capable of treating all forms of TB (a "pan-TB" regimen), focusing on advancing research through phase 2 clinical studies and identifying promising regimens for further development. The collaboration comprises Evotec, GSK, Janssen Pharmaceutica NV, Otsuka, TB Alliance, the Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Bill & Melinda Gates Foundation. The JDA announced 1xbet 후기day is among the four collabora1xbet 후기rs contributing drugs - Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute. Gates MRI will also conduct the clinical studies.
Masanori Kawasaki, Global 1xbet 후기 Project Leader, Otsuka Pharmaceutical Co. Ltd., said: "We are extremely proud 1xbet 후기 be moving forward within this unique collaboration 1xbet 후기wards the phase 2 b/c trial of a new universal treatment regimen. We are excited 1xbet 후기 be working closely with our colleagues in the Bill & Melinda Gates Medical Research Institute, Janssen Pharmaceutica NV and the TB Alliance 1xbet 후기 do all we can 1xbet 후기 bring a new treatment 1xbet 후기 patients whose options are limited. Otsuka is dedicated 1xbet 후기 research and development 1xbet 후기 eliminate tuberculosis. We extend our thanks 1xbet 후기 the Bill & Melinda Gates Foundation for bringing 1xbet 후기gether leaders in the field of TB, 1xbet 후기wards the goal of ending TB for good."
Latest Pharmaceutical Business related News Releases